EE167 Use of Cost per Responder Models for CAR-T Therapies in Relapsed or Refractory Multiple Myeloma

Chimeric antigen receptor T-cell (CAR-T) therapies targeting the B-cell maturation are a new class of therapy for treating Relapsed or Refractory Multiple Myeloma (RRMM). As CAR-T introduced, payers will need to balance higher efficacy, upfront costs, and total treatment costs when evaluating potential value. We developed cost per responder (CPR) model which incorporates efficacy evaluate value RRMM (ciltacabtagene autoleucel [cilta-cel] idecabtagene vicleucel [ide-cel]). Without available head-to-head trial data, unanchored matching adjusted indirect comparisons (MAIC) were used comparative cilta-cel ide-cel in CPR model. MAIC results indicated that was associated with statistically significant improved overall response rate (odds ratio [OR]: 94.93 [95% confidence interval [CI]: 21.86, 412.25; p<.0001]), complete better (OR: 5.65 CI: 2.51, 12.69; p<.0001]) progression-free survival (PFS) (hazard ratio: 0.37 0.24, 0.59; compared ide-cel. To estimate analysis also included apheresis, bridging therapy, acquisition administration, supportive care monitoring, adverse event management, any delivery inpatient outpatient clinical services. A time horizon approximately 31 months based on follow-up times from CARTITUDE-1 KarMMa trials. Preliminary indicate is an approximate $763,000, $1,710,000, month PFS $50,000. Corresponding be generated closer PDUFA date (February 28, 2022) presented at ISPOR 2022. models have support newer, more innovative by incorporating information both costs.